Acumen Pharmaceuticals (ABOS) Enterprise Value (2020 - 2026)
Acumen Pharmaceuticals (ABOS) posted Enterprise Value of -$128.0 million for Q1 2026, down 9.53% sequentially from -$116.9 million in Q4 2025, and up 14.18% YoY from -$112.1 million in Q1 2025.
Acumen Pharmaceuticals (ABOS) Enterprise Value (2020 - 2026) Analysis & Trends
Acumen Pharmaceuticals has reported Enterprise Value for 7 years, with the latest figure at -$128.0 million in Q1 2026.
- Quarterly Enterprise Value rose 14.18% year-over-year to -$128.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$128.0 million (up 14.18% YoY) and the FY2025 annual result came in at -$116.9 million, up 31.75% from the prior year.
- Enterprise Value slipped to -$128.0 million in Q1 2026 per ABOS's latest filing, from -$116.9 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$116.9 million in Q4 2025 and troughed at -$260.5 million in Q2 2024.
- A 5-year average of -$179.3 million and a median of -$177.6 million in 2022 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2025: Enterprise Value sank 416.06% in 2022, then surged 44.96% in 2025.
- Over 5 years, Enterprise Value stood at -$177.6 million in 2022, then tumbled by 36.73% to -$242.8 million in 2023, then rose by 29.49% to -$171.2 million in 2024, then jumped by 31.75% to -$116.9 million in 2025, then fell by 9.53% to -$128.0 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$128.0 million, -$116.9 million, and -$126.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.56 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.72 Bn | 60.53 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.75 Bn | 53.61 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.59 Bn | 10.19 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.63 Bn | 26.47 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.24 Bn | 26.40 Bn | - | 2.12 Bn |
| 10 | Acumen Pharmaceuticals | 237.55 Mn | 237.55 Mn | - | -110.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -110.20 Mn |
| Mar 31, 2026 | -128.00 Mn |
| Dec 31, 2025 | -116.87 Mn |
| Sep 30, 2025 | -126.61 Mn |
| Jun 30, 2025 | -143.37 Mn |
| Mar 31, 2025 | -149.15 Mn |
| Dec 31, 2024 | -171.23 Mn |
| Sep 30, 2024 | -199.96 Mn |
| Jun 30, 2024 | -260.47 Mn |
| Mar 31, 2024 | -252.51 Mn |
| Dec 31, 2023 | -242.84 Mn |
| Sep 30, 2023 | -215.43 Mn |
| Jun 30, 2023 | -144.88 Mn |
| Mar 31, 2023 | -140.41 Mn |
| Dec 31, 2022 | -177.61 Mn |
| Sep 30, 2022 | -200.19 Mn |
| Jun 30, 2022 | -189.91 Mn |
| Mar 31, 2022 | -189.09 Mn |
| Dec 31, 2021 | -194.24 Mn |
| Sep 30, 2021 | -198.96 Mn |